U.S. markets close in 1 hour 20 minutes
  • S&P 500

    4,288.33
    -109.61 (-2.49%)
     
  • Dow 30

    33,521.49
    -743.88 (-2.17%)
     
  • Nasdaq

    13,413.38
    -355.54 (-2.58%)
     
  • Russell 2000

    1,988.29
    +0.37 (+0.02%)
     
  • Crude Oil

    83.45
    -1.69 (-1.98%)
     
  • Gold

    1,840.00
    +8.20 (+0.45%)
     
  • Silver

    23.86
    -0.46 (-1.89%)
     
  • EUR/USD

    1.1329
    -0.0026 (-0.23%)
     
  • 10-Yr Bond

    1.7280
    -0.0190 (-1.09%)
     
  • GBP/USD

    1.3479
    -0.0066 (-0.49%)
     
  • USD/JPY

    113.6800
    +0.0250 (+0.02%)
     
  • BTC-USD

    35,808.96
    +739.86 (+2.11%)
     
  • CMC Crypto 200

    812.92
    +2.32 (+0.29%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,588.37
    +66.11 (+0.24%)
     

3 Reasons Why Novavax Stock Will Likely Beat Moderna Over the Next Year

·4 min read
3 Reasons Why Novavax Stock Will Likely Beat Moderna Over the Next Year
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • NVAX
  • MRNA

Moderna (NASDAQ: MRNA) has hands-down delivered the best stock performance among leading COVID-19 vaccine makers over the last 12 months. As much as I admire Moderna's innovation, though, I don't think it will be the biggest winner among vaccine stocks over the next year. Instead, my view is that Novavax (NASDAQ: NVAX) could emerge from the pack to trounce it, and there are three reasons why.